Rivoceranib

DB14765InvestigationalSmall molecule

Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor 2
Curator reviewed
Formula / weight: C₂₄H₂₃N₅O · 397.482 g/mol (avg)
Also known as: Apartinib · Apatinib · YN968D1 free base

Resolves to

Compound

Structure

InChIKeyWPEWQEMJFLWMLV-UHFFFAOYSA-NSMILESO=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1

Targets

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

446Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rivoceranib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.